On Thursday November 21, the Ohio State University TTP & aHUS offered a virtual and in-person support group.
Answering TTP Foundation had committed almost $2 million to research grants through 2021 thanks to our grass-roots fundraising campaigns like International TTP Day. The 2019 research competition attracted research proposals from North America and Europe. Proposals were peer reviewed by other TTP researchers and physicians. The winner was selected based on scientific merit.
The ISTH welcomes the public to comment on its draft recommendations for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP) via online survey only by October 21.
Answering TTP Foundation will submit feedback reviewed by a panel of patients and supporters. Clinicians, researchers, allied health professionals, policy makers, industry representatives, patients, caregivers, and other members of the public have been invited to contribute to this process.
Mina is helping to spread education about TTP.
2018 International TTP Day participant fundraising directly impacts the Foundation's ability to provide ground breaking research funding.
The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.
The European Commission has granted marketing authorization for caplacizumab for the treatment of adults experiencing an episode of aTTP on August 31, 2018.